Anti-VEGF treatment has recently been shown to be effective for retinopathy of prematurity (ROP), an eye disease that can occur in some premature babies born before 31 weeks. ROP is an important cause of severe visual impairment in childhood. While managed care professionals are familiar with available biologics targeting vascular endothelial growth factor, the nuances of their use and expanding indications remain an educational need. In particular, education is lacking regarding emerging pharmacologic treatment strategies for ROP.
- Provider:Medical Education Resources
- Activity Link: https://www.impactedu.net
- Start Date: 2023-09-30 05:00:00
- End Date: 2023-09-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 7500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest